Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis - PubMed (original) (raw)

Comparative Study

doi: 10.1136/gut.44.6.789.

S Staibano, A Rocco, E Mezza, F P D'armiento, L Insabato, A Coppola, G Salvatore, A Lucariello, N Figura, G De Rosa, G Budillon

Affiliations

Comparative Study

Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis

G Nardone et al. Gut. 1999 Jun.

Erratum in

Abstract

Background: Helicobacter pylori, the main cause of chronic gastritis, is a class I gastric carcinogen. Chronic gastritis progresses to cancer through atrophy, metaplasia, and dysplasia. Precancerous phenotypic expression is generally associated with acquired genomic instability.

Aim: To evaluate the effect of H pylori infection and its eradication on gastric histology, cell proliferation, DNA status, and oncogene expression.

Methods/subjects: Morphometric and immunohistochemical techniques were used to examine gastric mucosal biopsy specimens from eight controls, 10 patients with H pylori negative chronic gastritis, 53 with H pylori positive chronic gastritis, and 11 with gastric cancer.

Results: All patients with chronic gastritis were in a hyperproliferative state related to mucosal inflammation, regardless of H pylori infection. Atrophy was present in three of 10 patients with H pylori negative chronic gastritis and in 26 of 53 with H pylori positive chronic gastritis, associated in 18 with intestinal metaplasia. DNA content was abnormal in only 11 patients with atrophy and H pylori infection; eight of these also had c-Myc expression, associated in six cases with p53 expression. Fifty three patients with H pylori positive chronic gastritis were monitored for 12 months after antibiotic treatment: three dropped out; infection was eradicated in 45, in whom cell proliferation decreased in parallel with the reduction in gastritis activity; atrophy previously detected in 21/45 disappeared in five, regressed from moderate to mild in nine, and remained unchanged in seven; complete metaplasia disappeared in 4/14, and markers of genomic instability disappeared where previously present. In the five patients in whom H pylori persisted, atrophy, metaplasia, dysplasia, and markers of genomic instability remained unchanged.

Conclusions: Chronic H pylori infection seems to be responsible for genomic instability in a subset of cases of H pylori positive chronic atrophic gastritis; eradication of H pylori infection can reverse inflammation and the related atrophy, metaplasia, and genomic instability.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Distribution of histological and immunohistochemical features and DNA content in 53 H pylori positive patients with chronic gastritis. *16 complete and two incomplete.

Figure 2

Figure 2

Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in gastric crypt sections (as indicated on the figure; a mean of five well oriented crypts for each patient) of patients with functional dyspepsia, H pylori negative chronic gastritis, or H pylori positive chronic gastritis, with or without complete intestinal metaplasia (IM), before and after H pylori eradication. LI, labelling index, expressed as percentage of PCNA positive nuclei; C, controls with functional dyspepsia; nCG, H pylori negative chronic gastritis; pCG IM−, H pylori positive chronic gastritis without intestinal metaplasia; pCG IM+, H pylori positive chronic gastritis with complete intestinal metaplasia; IM−, chronic gastritis without intestinal metaplasia after H pylori eradication; IM+, chronic gastritis with intestinal metaplasia after H pylori eradication. †Three patients dropped out; intestinal metaplasia disappeared in four subjects.

Figure 3

Figure 3

Proliferating cell nuclear antigen (PCNA) immunostaining of the gastric mucosa. (A) H pylori negative chronic gastritis with expression of PCNA in the nuclei of the cells of the glandular neck; (B) H pylori positive chronic gastritis; (C) H pylori positive chronic gastritis with intestinal metaplasia; (D) H pylori positive chronic gastritis after successful eradication treatment; (E) invasive gastric cancer showing high levels of PCNA positivity. Note the low labelling index of PCNA in the adjacent normal mucosa. Original magnifications: A, × 250; B, × 150; C × 400; D, × 250; E, × 150.

Figure 4

Figure 4

Silver stained nucleolar organiser regions (AgNORs) in gastric mucosa. (A) H pylori negative chronic gastritis: small to medium-sized AgNORs in the nuclei. (B) H pylori positive chronic gastritis: medium-sized irregular AgNORs in the nuclei. (C) H pylori positive chronic gastritis, after eradication treatment. (D) Gastric cancer: large, irregular and sometimes unusually shaped AgNORs in neoplastic cells. Original magnification: A, B, C and D, × 1000, oil immersion.

Figure 5

Figure 5

bcl-2 protein expression. (A) H pylori negative chronic gastritis: moderate bcl-2 expression. (B) H pylori positive chronic gastritis. (C) H pylori positive chronic gastritis with dysplasia: low bcl-2 expression. (D) H pylori positive chronic gastritis: moderate expression of bcl-2 protein in areas of intestinal metaplasia. (E) Nodal metastasis from gastric cancer: negative for bcl-2 protein in gastric cancer cells. Original magnifications: A, × 250; B, × 250; C, × 400; D, × 250; E, × 100.

Figure 6

Figure 6

Representative DNA ploidy patterns in Feulgen stained sections of gastric mucosa. (A) H pylori positive chronic gastritis with moderate dysplasia: mild degree of aneuploidy. (B) H pylori positive chronic gastritis not responsive to eradication therapy without dysplasia: mild degree of aneuploidy. (C) Aneuploid pattern in gastric cancer (image analysis Quantimet 500C).

Figure 7

Figure 7

c-Myc expression. (A) H pylori positive chronic gastritis: low to moderate positivity for c-Myc expression. (B) H pylori positive chronic gastritis with intestinal metaplasia: moderate degree of positivity for c-Myc protein. (C) Gastric cancer: positivity for neoplastic cells for c-Myc protein. Original magnifications: A, × 400; B × 400; C × 100.

Figure 8

Figure 8

p53 protein expression. (A) H pylori positive chronic gastritis: sparse low positivity for p53 protein. (B) H pylori positive chronic gastritis with intestinal metaplasia: positivity for p53 protein in areas of intestinal metaplasia. (C) Gastric cancer: high positivity for p53 protein. Original magnifications: A, × 250; B, × 250; C, × 100.

References

    1. Infect Immun. 1992 May;60(5):1858-63 -PubMed
    1. Br J Cancer. 1992 Sep;66(3):558-62 -PubMed
    1. Nature. 1992 Oct 8;359(6395):552-4 -PubMed
    1. Nature. 1992 Oct 8;359(6395):554-6 -PubMed
    1. Nature. 1992 Jul 2;358(6381):15-6 -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources